September 2, 2022
Increased Risk of Endothelial Dysfunction in Patients With Alopecia Areata
Patients with alopecia areata (AA) may have an increased risk of endothelial dysfunction and subsequent cardiovascular complications. A case-control study found that patients with AA had lower reactive hyperemia index (RHI) scores than patients without AA, indicating the potential need for routine cardiovascular screening in patients with AA. As a chronic autoimmune disease, alopecia areata...
Shared Decision-Making Improves Patient-Reported Quality of Treatment for Alopecia Areata
Shared decision-making (SDM) is a crucial aspect of ensuring patients with alopecia areata (AA) are satisfied with the quality of their treatment. Clinicians are encouraged to implement SDM as often as possible when devising a treatment strategy for patients with AA. The treatment landscape for alopecia areata (AA) can be complex to navigate. With several...
Current Standards and Challenges of ATTR-CM Treatments
Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are faced with different possibilities for treating their symptoms and underlying disease. However, treatment options may vary depending on the severity of the disease, the cost of the treatment, and other factors. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive disease that primarily affects the heart, although it can...